These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 21536983)
21. [Influence of nebivolol on left ventricular remodeling in patients with arterial hypertension without chronic heart failure]. Khurs EM; Zinov'eva IuA; Poddubnaia AV; Smolenskaia OG Kardiologiia; 2007; 47(12):15-9. PubMed ID: 18260973 [TBL] [Abstract][Full Text] [Related]
22. Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. Hayek SS; Poole JC; Neuman R; Morris AA; Khayata M; Kavtaradze N; Topel ML; Binongo JG; Li Q; Jones DP; Waller EK; Quyyumi AA J Am Soc Hypertens; 2015 Mar; 9(3):206-13. PubMed ID: 25681236 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Germino FW Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484 [TBL] [Abstract][Full Text] [Related]
24. Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension. Galderisi M; D'Errico A; Sidiropulos M; Innelli P; de Divitiis O; de Simone G J Hypertens; 2009 Oct; 27(10):2108-15. PubMed ID: 19564794 [TBL] [Abstract][Full Text] [Related]
25. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Triposkiadis F; Giamouzis G; Kelepeshis G; Sitafidis G; Skoularigis J; Demopoulos V Int J Clin Pharmacol Ther; 2007 Feb; 45(2):71-7. PubMed ID: 17323786 [TBL] [Abstract][Full Text] [Related]
26. Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension. Fici F; Celik T; Balta S; Iyisoy A; Unlu M; Demitkol S; Yaman H; Brambilla G; Kardesoglu E; Kilic S; Yokusoglu M; Grassi G J Cardiovasc Pharmacol; 2013 Oct; 62(4):388-93. PubMed ID: 23921307 [TBL] [Abstract][Full Text] [Related]
27. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Van Nueten L; Lacourcière Y; Vyssoulis G; Korlipara K; Marcadet DM; Dupont AG; Robertson JI Am J Ther; 1998 Jul; 5(4):237-43. PubMed ID: 10099065 [TBL] [Abstract][Full Text] [Related]
28. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. van Merode T; van Bortel LM; Smeets FA; Mooij JM; Bohm RO; Rahn KH; Reneman RS J Hypertens Suppl; 1989 Dec; 7(6):S262-3. PubMed ID: 2576665 [TBL] [Abstract][Full Text] [Related]
29. [Pulse pressure, arterial compliance and Buckberg index in hypertensive patients treated with nebivolol and nitrates]. Prisadă OV; Covic A; Arghiri E; Cernomaz A; Ungureanu G Rev Med Chir Soc Med Nat Iasi; 2007; 111(2):352-7. PubMed ID: 17983167 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers. Patel RS; Sharma KH; Kamath NA; Patel NH; Thakkar AM Indian J Pharmacol; 2014; 46(5):485-9. PubMed ID: 25298575 [TBL] [Abstract][Full Text] [Related]
31. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. Celik T; Iyisoy A; Kursaklioglu H; Kardesoglu E; Kilic S; Turhan H; Yilmaz MI; Ozcan O; Yaman H; Isik E; Fici F J Hypertens; 2006 Mar; 24(3):591-6. PubMed ID: 16467663 [TBL] [Abstract][Full Text] [Related]
32. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. Makolkin VI; Akhmedova OO; Buval'tsev VI; Gavrilov IuV; Petriĭ VV Kardiologiia; 2003; 43(2):40-3. PubMed ID: 12891271 [TBL] [Abstract][Full Text] [Related]
33. Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study. Vaz-de-Melo RO; Giollo-Júnior LT; Martinelli DD; Moreno-Júnior H; Mota-Gomes MA; Cipullo JP; Yugar-Toledo JC; Vilela-Martin JF Sao Paulo Med J; 2014; 132(5):290-6. PubMed ID: 25054966 [TBL] [Abstract][Full Text] [Related]
34. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. Van Bortel LM; Breed JG; Joosten J; Kragten JA; Lustermans FA; Mooij JM J Cardiovasc Pharmacol; 1993 Jun; 21(6):856-62. PubMed ID: 7687708 [TBL] [Abstract][Full Text] [Related]
35. [Short-term effect of nebivolol on the left ventricular diastolic function]. Demiralp E; Kardeşoğlu E; Celik T; Cebeci BS; Ozmen N; Işilak Z; Ulusoy RE; Dinçtürk M Anadolu Kardiyol Derg; 2004 Dec; 4(4):323-36. PubMed ID: 15590361 [TBL] [Abstract][Full Text] [Related]
36. The role of the new beta-blockers in treating cardiovascular disease. Weber MA Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195 [TBL] [Abstract][Full Text] [Related]
37. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Hashimoto J; Imai Y; O'Rourke MF Am J Hypertens; 2007 Apr; 20(4):378-84. PubMed ID: 17386343 [TBL] [Abstract][Full Text] [Related]
38. The antihypertensive and cardiac hemodynamic effects of nebivolol. DeCrée J; Van Rooy P; Geukens H; Haeverans K; Verhaegen H Angiology; 1992 May; 43(5):369-77. PubMed ID: 1348916 [TBL] [Abstract][Full Text] [Related]
39. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780 [TBL] [Abstract][Full Text] [Related]
40. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Cağlar N; Dincer I Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1359-68. PubMed ID: 22288296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]